Hormonal
Liraglutide 3.0 mg significantly reduces Obstructive Sleep Apnea (OSA) severity, measured by Apnea-Hypopnea Index (AHI), in individuals with obesity and moderate-to-severe OSA who are unable or unwilling to use CPAP therapy.
If you have moderate to severe sleep apnea and obesity, and you can't or won't use a CPAP machine, ask your doctor about Liraglutide 3.0 mg. It is a once-daily injection that helps you lose weight and significantly reduces the number of times you stop breathing during sleep. The most common side effects are nausea and diarrhea, but these usually go away after a few weeks. It works best when combined with a healthy diet and exercise.
After 32 weeks, the mean reduction in AHI was greater with liraglutide than with placebo (−12.2 vs − 6.1 events h − 1, estimated treatment difference: − 6.1 events h − 1 (95% confidence interval (CI), − 11.0 to − 1.2), P = 0.0150).
Why this rating
Randomized, double-blind, placebo-controlled trial with a large sample size (n=359) and rigorous statistical analysis.
Source
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
on behalf of the SCALE study group et al. · International Journal of Obesity · 2016
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →